Document is current

Any future updates will be listed below

Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Crossref DOI link: https://doi.org/10.1007/s13300-021-01011-3

Published Online: 2021-02-14

Published Print: 2021-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark